CN118773199A - 通过对cd163靶向灭活来改善猪类健康的方法 - Google Patents
通过对cd163靶向灭活来改善猪类健康的方法 Download PDFInfo
- Publication number
- CN118773199A CN118773199A CN202410894567.1A CN202410894567A CN118773199A CN 118773199 A CN118773199 A CN 118773199A CN 202410894567 A CN202410894567 A CN 202410894567A CN 118773199 A CN118773199 A CN 118773199A
- Authority
- CN
- China
- Prior art keywords
- seq
- nos
- edited
- gene
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010009992 CD163 antigen Proteins 0.000 title claims abstract description 312
- 238000000034 method Methods 0.000 title claims abstract description 113
- 230000036541 health Effects 0.000 title description 9
- 230000002779 inactivation Effects 0.000 title description 7
- 241000282887 Suidae Species 0.000 claims abstract description 128
- 101150087379 CD163 gene Proteins 0.000 claims abstract description 105
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 34
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims abstract description 20
- 108020005004 Guide RNA Proteins 0.000 claims description 263
- 210000004027 cell Anatomy 0.000 claims description 218
- 125000003729 nucleotide group Chemical group 0.000 claims description 132
- 239000002773 nucleotide Substances 0.000 claims description 130
- 108091033409 CRISPR Proteins 0.000 claims description 46
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims description 46
- 235000013601 eggs Nutrition 0.000 claims description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 41
- 238000012217 deletion Methods 0.000 claims description 39
- 230000037430 deletion Effects 0.000 claims description 39
- 210000002950 fibroblast Anatomy 0.000 claims description 37
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 30
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000002513 implantation Methods 0.000 claims 2
- 241001465754 Metazoa Species 0.000 abstract description 234
- 108090000623 proteins and genes Proteins 0.000 abstract description 134
- 241000282898 Sus scrofa Species 0.000 abstract description 127
- 238000010362 genome editing Methods 0.000 abstract description 81
- 108700028369 Alleles Proteins 0.000 abstract description 51
- 239000000203 mixture Substances 0.000 abstract description 20
- 230000000415 inactivating effect Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 description 98
- 102000004169 proteins and genes Human genes 0.000 description 81
- 235000018102 proteins Nutrition 0.000 description 77
- 108020004414 DNA Proteins 0.000 description 62
- 239000000523 sample Substances 0.000 description 41
- 125000006850 spacer group Chemical group 0.000 description 41
- 210000002257 embryonic structure Anatomy 0.000 description 40
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 37
- 101710163270 Nuclease Proteins 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 36
- 210000000287 oocyte Anatomy 0.000 description 34
- 238000000338 in vitro Methods 0.000 description 33
- 230000033616 DNA repair Effects 0.000 description 31
- 108010042407 Endonucleases Proteins 0.000 description 31
- 230000006780 non-homologous end joining Effects 0.000 description 31
- 238000003776 cleavage reaction Methods 0.000 description 29
- 210000001161 mammalian embryo Anatomy 0.000 description 29
- 230000007017 scission Effects 0.000 description 29
- 108020004705 Codon Proteins 0.000 description 26
- 108091079001 CRISPR RNA Proteins 0.000 description 25
- 102100031780 Endonuclease Human genes 0.000 description 25
- 241000193996 Streptococcus pyogenes Species 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 210000002459 blastocyst Anatomy 0.000 description 21
- 230000002068 genetic effect Effects 0.000 description 19
- 244000144980 herd Species 0.000 description 19
- 230000008685 targeting Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 230000001404 mediated effect Effects 0.000 description 17
- 102000040430 polynucleotide Human genes 0.000 description 17
- 108091033319 polynucleotide Proteins 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 16
- 230000004720 fertilization Effects 0.000 description 16
- 230000001605 fetal effect Effects 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 241000194020 Streptococcus thermophilus Species 0.000 description 15
- 238000005520 cutting process Methods 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 230000001488 breeding effect Effects 0.000 description 14
- 230000005782 double-strand break Effects 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 238000003753 real-time PCR Methods 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 238000009395 breeding Methods 0.000 description 13
- 210000000349 chromosome Anatomy 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 238000010453 CRISPR/Cas method Methods 0.000 description 12
- 230000014616 translation Effects 0.000 description 12
- 230000009027 insemination Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108091093088 Amplicon Proteins 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000009438 off-target cleavage Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108020005038 Terminator Codon Proteins 0.000 description 8
- 238000002306 biochemical method Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 101100382101 Sus scrofa CD163 gene Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 210000003101 oviduct Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 102000004533 Endonucleases Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000021050 feed intake Nutrition 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000004547 gene signature Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000009931 harmful effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 108060002716 Exonuclease Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 102000013165 exonuclease Human genes 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 230000007018 DNA scission Effects 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000000205 computational method Methods 0.000 description 4
- 210000001771 cumulus cell Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000002445 nipple Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000003766 bioinformatics method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000012350 deep sequencing Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 108091005725 scavenger receptor cysteine-rich superfamily Proteins 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 208000002254 stillbirth Diseases 0.000 description 3
- 231100000537 stillbirth Toxicity 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 206010003883 azoospermia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000010807 real-time PCR kit Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000005132 reproductive cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- VOOGILFUHUXBEV-ZBRNBAAYSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound OC[C@H](N)C(O)=O.OC(=O)[C@@H]1CCCN1 VOOGILFUHUXBEV-ZBRNBAAYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- ZPXCNXMJEZKRLU-LSJOCFKGSA-N Ala-His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 ZPXCNXMJEZKRLU-LSJOCFKGSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010066799 Heterochromia iridis Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010042778 Syndactyly Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 208000031900 Woolly hair Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 208000019692 familial woolly hair syndrome Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000000604 fetal stem cell Anatomy 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000012237 germline editing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000026847 isolated familial woolly hair disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000014987 limb edema Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- CMIAIUZBKPLIOP-YZLZLFLDSA-N methyl (1r,4ar,4br,10ar)-7-(2-hydroperoxypropan-2-yl)-4a-methyl-2,3,4,4b,5,6,10,10a-octahydro-1h-phenanthrene-1-carboxylate Chemical compound C1=C(C(C)(C)OO)CC[C@@H]2[C@]3(C)CCC[C@@H](C(=O)OC)[C@H]3CC=C21 CMIAIUZBKPLIOP-YZLZLFLDSA-N 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 238000002888 pairwise sequence alignment Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 208000003580 polydactyly Diseases 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 208000028280 polygenic inheritance Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 206010038433 renal dysplasia Diseases 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8778—Swine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/124—Animal traits, i.e. production traits, including athletic performance or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Animal Husbandry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020128P | 2020-05-05 | 2020-05-05 | |
| US63/020,128 | 2020-05-05 | ||
| US202063021370P | 2020-05-07 | 2020-05-07 | |
| US63/021,370 | 2020-05-07 | ||
| CN202110489495.9A CN113151291B (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110489495.9A Division CN113151291B (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118773199A true CN118773199A (zh) | 2024-10-15 |
Family
ID=75954141
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410894567.1A Pending CN118773199A (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
| CN202410894582.6A Pending CN118879712A (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
| CN202410894572.2A Pending CN118620905A (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
| CN202110489495.9A Active CN113151291B (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
| CN202311146361.2A Active CN117487855B (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410894582.6A Pending CN118879712A (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
| CN202410894572.2A Pending CN118620905A (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
| CN202110489495.9A Active CN113151291B (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
| CN202311146361.2A Active CN117487855B (zh) | 2020-05-05 | 2021-05-06 | 通过对cd163靶向灭活来改善猪类健康的方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US11208659B2 (https=) |
| EP (1) | EP4145991A1 (https=) |
| JP (1) | JP2023525263A (https=) |
| KR (1) | KR20230006827A (https=) |
| CN (5) | CN118773199A (https=) |
| AU (1) | AU2021268263A1 (https=) |
| BR (1) | BR112022020072A2 (https=) |
| CA (1) | CA3179710A1 (https=) |
| MX (1) | MX2022013704A (https=) |
| WO (1) | WO2021224599A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3179710A1 (en) * | 2020-05-05 | 2021-11-11 | Andrew Mark CIGAN | Methods for improving the health of porcine species by targeted inactivation of cd163 |
| US20250064032A1 (en) | 2021-12-10 | 2025-02-27 | Pig Improvement Company Uk Limited | Editing tmprss2/4 for disease resistance in livestock |
| WO2024097603A2 (en) * | 2022-11-02 | 2024-05-10 | Abs Global, Inc. | Method of creating gene edited animals comprising a wild type allele |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103687482A (zh) * | 2011-05-16 | 2014-03-26 | 密苏里大学管理者 | 抗猪生殖与呼吸综合征病毒的动物 |
| WO2017023337A1 (en) * | 2015-08-06 | 2017-02-09 | The Curators Of The University Of Missouri | Pathogen-resistant animals having modified cd163 genes |
| CN108753832A (zh) * | 2018-04-20 | 2018-11-06 | 中山大学 | 一种利用CRISPR/Cas9编辑大白猪CD163基因的方法 |
| CN109475107A (zh) * | 2015-08-06 | 2019-03-15 | 密苏里大学管理者 | 具有修饰的cd163基因的抗病原体动物 |
| CN109666646A (zh) * | 2018-11-15 | 2019-04-23 | 广东省农业科学院农业生物基因研究中心 | 一种cd163基因编辑的猪胚胎成纤维细胞系的制备及应用 |
| CN109862786A (zh) * | 2016-10-17 | 2019-06-07 | 爱丁堡大学董事会 | 包含改性cd163的猪及相关方法 |
| WO2019119521A1 (zh) * | 2017-12-18 | 2019-06-27 | 中山大学 | 一种抗蓝耳病Marc-145细胞系及其制备方法和应用 |
| CN113151291A (zh) * | 2020-05-05 | 2021-07-23 | 吉纳斯公司 | 通过对cd163靶向灭活来改善猪类健康的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US20140068727A1 (en) | 2012-09-05 | 2014-03-06 | Apple Inc. | Wi-fi credential sharing using images |
| GB201313235D0 (en) * | 2013-07-24 | 2013-09-04 | Univ Edinburgh | Antiviral Compositions Methods and Animals |
| CN104593422A (zh) * | 2015-01-08 | 2015-05-06 | 中国农业大学 | 一种抗蓝耳病克隆猪的制备方法 |
| CN107177595A (zh) * | 2017-06-07 | 2017-09-19 | 浙江大学 | 用于猪CD163基因编辑的靶向sgRNA、修饰载体及其制备方法和应用 |
| CN107354170A (zh) * | 2017-08-24 | 2017-11-17 | 中国农业科学院北京畜牧兽医研究所 | 一种基因敲除载体以及制备cd163基因敲除猪成纤维细胞的方法 |
| KR102680060B1 (ko) | 2018-04-17 | 2024-07-02 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | 바이러스에 의한 감염으로부터 돼지 태아를 보호하는 방법 |
| CN108823248A (zh) * | 2018-04-20 | 2018-11-16 | 中山大学 | 一种利用CRISPR/Cas9编辑陆川猪CD163基因的方法 |
| CN109055385B (zh) * | 2018-08-21 | 2021-08-27 | 吉林大学 | 一种有效抑制ⅱ型prrsv感染的基因序列及其应用 |
| CN110951745A (zh) * | 2019-10-30 | 2020-04-03 | 内蒙古大学 | Cd163突变基因及其在抑制或阻断猪产生抗体的方法和应用 |
-
2021
- 2021-05-04 CA CA3179710A patent/CA3179710A1/en active Pending
- 2021-05-04 WO PCT/GB2021/051060 patent/WO2021224599A1/en not_active Ceased
- 2021-05-04 MX MX2022013704A patent/MX2022013704A/es unknown
- 2021-05-04 BR BR112022020072A patent/BR112022020072A2/pt unknown
- 2021-05-04 US US17/307,369 patent/US11208659B2/en active Active
- 2021-05-04 KR KR1020227038847A patent/KR20230006827A/ko active Pending
- 2021-05-04 EP EP21726165.0A patent/EP4145991A1/en active Pending
- 2021-05-04 JP JP2022567585A patent/JP2023525263A/ja active Pending
- 2021-05-04 AU AU2021268263A patent/AU2021268263A1/en active Pending
- 2021-05-06 CN CN202410894567.1A patent/CN118773199A/zh active Pending
- 2021-05-06 CN CN202410894582.6A patent/CN118879712A/zh active Pending
- 2021-05-06 CN CN202410894572.2A patent/CN118620905A/zh active Pending
- 2021-05-06 CN CN202110489495.9A patent/CN113151291B/zh active Active
- 2021-05-06 CN CN202311146361.2A patent/CN117487855B/zh active Active
- 2021-10-29 US US17/515,139 patent/US12416005B2/en active Active
-
2022
- 2022-01-21 US US17/581,239 patent/US11535850B2/en active Active
-
2023
- 2023-03-29 US US18/192,492 patent/US12371692B2/en active Active
-
2025
- 2025-08-15 US US19/301,583 patent/US20260092277A1/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103687482A (zh) * | 2011-05-16 | 2014-03-26 | 密苏里大学管理者 | 抗猪生殖与呼吸综合征病毒的动物 |
| WO2017023337A1 (en) * | 2015-08-06 | 2017-02-09 | The Curators Of The University Of Missouri | Pathogen-resistant animals having modified cd163 genes |
| CN109475107A (zh) * | 2015-08-06 | 2019-03-15 | 密苏里大学管理者 | 具有修饰的cd163基因的抗病原体动物 |
| CN109862786A (zh) * | 2016-10-17 | 2019-06-07 | 爱丁堡大学董事会 | 包含改性cd163的猪及相关方法 |
| WO2019119521A1 (zh) * | 2017-12-18 | 2019-06-27 | 中山大学 | 一种抗蓝耳病Marc-145细胞系及其制备方法和应用 |
| CN108753832A (zh) * | 2018-04-20 | 2018-11-06 | 中山大学 | 一种利用CRISPR/Cas9编辑大白猪CD163基因的方法 |
| CN109666646A (zh) * | 2018-11-15 | 2019-04-23 | 广东省农业科学院农业生物基因研究中心 | 一种cd163基因编辑的猪胚胎成纤维细胞系的制备及应用 |
| CN113151291A (zh) * | 2020-05-05 | 2021-07-23 | 吉纳斯公司 | 通过对cd163靶向灭活来改善猪类健康的方法 |
Non-Patent Citations (1)
| Title |
|---|
| CHUNHE GUO等: "Highly Efficient Generation of Pigs Harboring a Partial Deletion of the CD163 SRCR5 Domain, Which Are Fully Resistant to Porcine Reproductive and Respiratory Syndrome Virus 2 Infection:pubmed, cd163 srcr5 exon crispr CD163 knockout pigs are fully resistant to highly pathogenic porcine reproductive a", FRONT IMMUNOL, vol. 10, 8 August 2019 (2019-08-08), pages 1 - 14 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3179710A1 (en) | 2021-11-11 |
| US20210348165A1 (en) | 2021-11-11 |
| US20220042017A1 (en) | 2022-02-10 |
| US20230272397A1 (en) | 2023-08-31 |
| US11535850B2 (en) | 2022-12-27 |
| CN117487855B (zh) | 2024-07-26 |
| MX2022013704A (es) | 2022-12-07 |
| US12371692B2 (en) | 2025-07-29 |
| BR112022020072A2 (pt) | 2022-11-29 |
| KR20230006827A (ko) | 2023-01-11 |
| US20260092277A1 (en) | 2026-04-02 |
| EP4145991A1 (en) | 2023-03-15 |
| JP2023525263A (ja) | 2023-06-15 |
| US20220135976A1 (en) | 2022-05-05 |
| AU2021268263A1 (en) | 2022-10-27 |
| US12416005B2 (en) | 2025-09-16 |
| US11208659B2 (en) | 2021-12-28 |
| CN113151291B (zh) | 2024-09-03 |
| CN113151291A (zh) | 2021-07-23 |
| CN118879712A (zh) | 2024-11-01 |
| CN117487855A (zh) | 2024-02-02 |
| WO2021224599A1 (en) | 2021-11-11 |
| CN118620905A (zh) | 2024-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6815986B2 (ja) | 大型家畜の接合体における標的化ゲノム編集 | |
| US12371692B2 (en) | Methods for improving the health of porcine species by targeted inactivation of CD163 | |
| CN107043787A (zh) | 一种基于CRISPR/Cas9获得MARF1定点突变小鼠模型的构建方法和应用 | |
| AU2026200102A1 (en) | Pathogen-resistant animals having modified cd163 genes | |
| US20190223417A1 (en) | Genetically modified animals having increased heat tolerance | |
| JP2018531003A6 (ja) | 向上した耐暑性を有する遺伝子改変動物 | |
| CN116887671B (zh) | 具有经修饰的肌肉生长抑制素基因的转基因动物 | |
| CN119020356A (zh) | 特异性识别猪CD163基因的成套sgRNA及其编码DNA与应用 | |
| HK40056214A (en) | Methods for improving the health of porcine species by targeted inactivation of cd163 | |
| CN112553207A (zh) | 一种实现绵羊FGF5基因精准突变的sgRNA、试剂盒和应用 | |
| リアン クイーン | Studies on genome editing techniques using CRISPR/Cas9 in porcine embryos | |
| CN116064665A (zh) | 猪hbb基因定点修饰系统及应用 | |
| CN121801900A (zh) | 一种精准高效的DNA-free基因编辑方法 | |
| WO2022012663A1 (zh) | 病毒不易感动物及其构建方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |